

### LEPHE STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)		
Balaji Venkataraman	)		
	)		
Application No.: 10/635,928	)	Examiner:	Not assigned
	)		
Filed: August 6, 2003	)	Art Unit:	Not assigned
	)		
For: VITAMIN COMPOSITIONS	)		

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Lisa C. Pavento Reg. No. 44,669

KILPATRICK STOCKTON LLP 1100 Peachtree Street Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500

Our Docket: 52761-0110 (286146)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 2, 2003.

Lisa C. Pavento - Reg. No. 44,669

ATLLIB02 22985.1

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperw

Substitute for Form 1449/A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 6

Com	plete if Known
Application Number	10/635,928
Filing Date	August 6, 2003
First Nam d Invent r	Venkataraman
Group Art Unit	
Examiner Name	
Attorney Docket Number	52761/286146

				U.S. PATENT DOCUMENT	S	
Examiner Initials	Cite No.1		nt d Code <sup>2</sup> f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pp., Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	5,494,678		Paradissis, et al.	02-27-1996	
	2.	5,563,126		Allen, et al.	10-08-1996	
	3.	5,795,873		Allen	08-18-1998	
	4.	5,801,161		Merkus	09-01-1998	
	5.	5,932,624		Herbert	08-03-1999	
	6.	5,962,048		Register	10-05-1999	
	7.	6,039,978		Bangs, et al.	03-21-2000	
	8.	6,048,846		Cochran	04-11-2000	
	9.	6,121,249		Weissman. et al.	09-19-2000	
	10.	6,127,370		Smith, et al.	10-03-2000	
	11.	6,207,651	B1	Allen, et al.	03-27-2001	
	12.	6,299,896	B1	Cooper, et al.	10-09-2001	
	13.	6,323,188	B1	Weissman	11-27-2001	
	14.	6,361,800	B1	Cooper, et al.	03-26-2002	
	15.	6,369,041	B2	Horrobin, et al.	04-09-2002	
	16.	6,479,545	B1	Levinson, et al.	11/12-2002	
	17.	6,528,496	B1	Allen, et al.	03-04-2003	
	18.	2002/0010148	A1	Horrobin, et al.	01-24-2002	
	19.	2002/0136711	A1	Cochran	09-26-2002	
	20.	2002/0146463	A1	Clayton	10-10-2002	
	21.	2003/0049352	A1	Mehansho, et al.	03-13-2003	
-	22.	2003/017136 (Abstract)	A1	Cruz, et al.	01-23-2003	

				FORE	IGN PATENT DOCUMENTS			
T			Foreign Patent Docume	nt		Date of Publication	Pp., Columns, Lines,	
Examiner Initials	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	23.	EP	0366480 (Abstract)	B1	Bar Ilan University	08-24-1994	-	
	24.	WO	96/11009 (Abstract)	A1	UK	04-18-1996		
	25.	WO	98/01157 (Abstract)	A1	WWK Trust, Worsley, Andrew Peter	01-15-1998		
	26.	WO	2000/056295 (Abstract)	A2	Kilgowan Limited	09-28-2000		
	27.	wo	2001/056609 (Abstract)	A1	Germany	08-09-2001		
	28.	WO	2002/087593 (Abstract)	A1	Cobalz Limited	11-07-2002		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language translation is attached. ATLLIB02 138545.2

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of the Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary

2 Sheet of 6

Com	plete if Known	
Application Numb r	10/635,928	
Filing Dat	August 6, 2003	
First Named Inventor	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	29.	ALTURA, BURTON M. and ALTURA, BELLA T., "Magnesium and Cardiovascular Biology: An	
		Important Link Between Cardiovascular Risk Factors and Atherogenesis," Cellular and Molecular	
		Biology Research, 1995, pp. 347-359, Vol. 41, No. 5.	
	30.	ANDERSSON, H.C., et al., "Long-Term Outcome in Treated Combined Methylmalonic Acidemia	1
		and Homocystinemia," Genet Med, May-June 1999, pp. 146-150. (Abstract)	
	31.	APPEL, LAWRENCE, J., et al., "A Clinical Trial of the Effects of Dietary Patterns on Blood	
		Pressure," N. Engl. J. Med, April 17, 1997, pp. 1117-1124, Vol. 336, No. 16.	
	32.	BASU, TAPAN K. and MANN, SARABJIT, "Vitamin B-6 Normalizes the Altered Sulfur Amino Acid	
		Status of Rats Fed Diets Containing Pharmacological Levels of Niacin Without Reducing Niacin's	
		Hypolipidemic Effects," J. Nutr., 1997, pp.117-121, Vol. 127.	
	33.	BLOOM, O. JOSH, et al., "Do Antioxidants (Vitamins C, E) Improve Outcomes in Patients With	1
		Coronary Artery Disease?" J. Fam. Prac., November 2002, p. 978, Vol. 51, No. 11.	
	34.	BLUMBERG, A., et al., "Vitamin Nutrition in Patients on Continuous Ambulatory Peritoneal	1
		Dialysis (CAPD)," Clin Nephrol, November 1983, pp. 244-250, Vol. 20, No. 5. (Abstract)	
	35.	BOUSHEY, CAROL J., et al., "A Quantitative Assessment of Plasma Homocysteine as a Risk	T
		Factor for Vascular Disease," JAMA, October 4, 1995, pp. 1049-1057, Vol. 274, No. 13.	
	36.	BRATTSTROM, L. E., et al., "Folic Acid – An Innocuous Means to Reduce Plasma	+
		Homocysteine," Scand J. Clin. Lab Invest., 1998, pp. 215-221, Vol. 48.	
	37.	BRATTSTROM, LARS E., et al., "Folic Acid Responsive Postmenopausal Homocysteinemia,	+
		Metabolism," November 1985, pp. 1073-1077, Vol. 34, No. 11.	
	38.	BRATTSTROM, LARS, et al., "Impaired Homocysteine Metabolism in Early-Onset Cerebral and	1
		Peripheral Occlusive Arterial Disease," Atherosclerosis, 1990, pp. 51-60, Vol. 81.	
	39.	CAMPBELL, BRUCE G., et al., "Do Calcium Supplements Prevent Postmenopausal Osteoporotic	+
		Fractures?" J of Fam Prac., March 2003, pp. 236-237, Vol. 52, No. 3.	
	40.	CHAMBERS, JOHN C., et al., "Improved Vascular Endothelial Function After Oral B Vitamins,"	+
		Circulation, Nov. 14, 2000, pp. 2479-2483, Vol. 102.	
	1	1	_L

Examiner Signature	Date Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3 of 6

Com	plete if Known	
Application Number	10/635,928	
Filing Dat	August 6, 2003	
First Named Inventor	Venkataraman	
Group Art Unit		
Examiner Name		
Attorney Docket Number	52761/286146	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	41.	CHAN, P., et al., "Randomized, Double-Blind, Placebo-Controled Study of the Safety and Efficacy	
		of Vitamin B Complex in the Treatment of Nocturnal Leg Cramps in Elderly Patients with	
		Hypertension," J Clin Pharmacol., 1998, pp. 1151-1154, Vol. 38, No. 12. (Abstract)	
-	42.	DOSHI, SAGAR N., et al., "Folic Acid Improves Endothelial Function in Coronary Artery Disease	1
		via Mechanisms Largely Independent of Homocysteine Lowering," Circulation, January 1/8, 2002,	
		pp. 23-26, Vol. 102.	
,	43.	DUDMAN, NICHOLAS P. B., et al., "Homocysteinemia: Depressed Plasma Serine Levels,"	1-
		Metabolism, February 1987, pp. 198-201, Vol. 36, No. 2.	
	44.	ELIAN, et al., "Hydroxocobalamin Reduces Hyperhomocysteinemia in End-Stage Renal Disease,"	
		Metabolism, July 2002, pp. 881-886, Vol. 51. (Abstract)	
	45.	FANG, JAMES C., et al., "Effect of Vitamins C and E on Progression of Transplant-Associated	-
		Arteriosclerosis: A Randomised Trial," The Lancet, March 30, 2002, pp. 1108-1113, Vol. 359.	
	46.	FRANKEN, D.G., et al., "Effect of Various Regimens of Vitamin B <sub>6</sub> , and Folic Acid on Mild	
		Hyperhomocysteinaemia in Vascular Patients," J. Inher. Metab. Dis., 1994, pp. 159-162, Vol. 17.	
<del></del>	47.	GABY, A. R., "Intravenous Nutrient Therapy: The Myers' Cocktail," Altern Med Rev, Oct. 2002,	1
		pp. 389-403.	
	48.	GARG, REKKA, et al., "Niacin Treatment Increases Plasma Homocyst(e)ine Levels," Am Heart J.,	1
		December 1999, pp 1082-1087, Vol. 138, No.6, Part 1.	
	49.	GOTTFRIES, C. G., "Pharmacological Treatment Strategies in Alzheimer Type Dementia," Eur	
		Neuropsychopharmacol, Nov. 1990, pp. 1-5. (Abstract)	
	50.	HAIDARI, MEHRAN, et al., "Enhanced Susceptibility to Oxidation and Diminished Vitamin E	<del> </del>
		Content of LDL from Patients with Stable Coronary Artery Disease," Clinical Chemistry, 2001, pp.	
		1234-1240, Vol. 47, No.7.	
	51.	HARPEY, JEAN-PAUL, et al., "Homocystinuria Caused by 5,10-Methylenetetrahydrofolate	+-
		Reductase Deficiency: A Case in an Infant Responding to Methionine, Folinic Acid, Pyridoxine,	
		and Vitamin B <sub>12</sub> Therapy," J Pediatrics, February 1981, pp. 275-278, Vol. 98, No. 2.	
	1		

Examiner		Date	
Signature		Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995

Substitute for Form 1449/A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4 of 6

Compl te if Known					
Application Numb r	10/635,928				
Filing Dat	August 6, 2003				
First Named Inv ntor	Venkataraman				
Group Art Unit					
Examiner Name					
Attorney Docket Number	52761/286146				

	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS					
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>			
	52.	HEINECKE, JAY W., "Is the Emperor Wearing Clothes?" Arterioscler Thromb Vasc Biol., August				
		2001, pp. 1261-1264, Vol. 21.				
	53.	HEINONEN, O.P., et al., "The Effect of Vitamin E and Beta Carotene on the Incidence of Lung				
		Cancer and Other Cancers in Male Smokers," TN Engl J Med, April 14, 1994, pp. 1029-1035, Vol.				
		330, No. 15.				
	54.	HENKIN, YAAKOV, et al., "Niacin Revisited: Clinical Observations on an Important But	†			
		Underutilized Drug," Am J Med, September 1991, pp. 239-246, Vol. 91.				
	55.	HERBERT, V., "The Inhibition and Promotion of Cancers by Folic Acid, Vitamin B <sub>12</sub> , and their	<del> </del>			
		Antagonists," American Chemical Society (ACS Symposium series), 1985, pp. 32-36, Vol. 277.				
_	56.	KAUL, NALINI, et al., "α-Tocopherol and Atherosclerosis," E.B.M., 2001, pp. 5-12, Vol. 226.				
	57.	KLERK, M., "Effect of Homocysteine Reduction by B-Vitamin Supplementation on Markers of	1			
		Clotting Activation," Thromb Haemost, Aug. 2002, pp. 230-235, Vol. 88.				
	58.	LIAO, FANGZI, et al., "Is Low Magnesium Concentration a Risk Factor For Coronary Heart	†			
		Disease? The Atherosclerosis Risk in Communities (ARIC) Study," Am Heart J, September 1998,				
		pp. 480-490, Vol. 136, No. 3.				
	59.	MARCHESONI, D., et al., "Menopause Rather than Estrogen Modifies Plasma Homocysteine				
		Levels," International Journal of Gynecology and Obstetrics, 2003, pp. 293-297, Vol. 81.				
	60.	MASON, JB and MILLER, J.W., "The Effects of Vitamins B12, B6, and Folate on Blood	<u> </u>			
		Homocysteine Levels," Ann NY Acad Sci., Sept. 30, 1992, pp. 197-203.				
	61.	NILSSON, K., et al., "Treatment of Cobalamin Deficiency in Dementia, Evaluated Clinically and				
		With Cerebral Blood Flow Measurements," Aging (Milano), June 2000, pp. 199-207, Vol. 12.				
	62.	OLSZEWSKI, ANDRZEJ J., et al., "Reduction of Plasma Lipid and Homocysteine Levels by	1			
		Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis,"				
		Atherosclersis, 1989, pp. 1-6, Vol. 75.				
	63.	ROSSI, A., et al., "Early-Onset Combined Methymalonic Aciduria and Homocystinuria:				
		Neuroradiologic Findings," Am J. Neuroradiol, March 2001, pp. 554-563, Vol. 22.				

		· · · · · · · · · · · · · · · · · · ·	
Ī			
Eveniner			
Examiner		Date	
Signature		1	
Cigitato.	<u> </u>	Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwolk Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

5 Sheet of 6

Com	plete if Known
Application Number	10/635,928
Filing Date	August 6, 2003
First Named Inventor	Venkataraman
Group Art Unit	
Examiner Name	
Attorney Docket Number	52761/286146

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	64.	ROSSOUW, JACQUES E., et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy	
		Postmenopausal Women" JAMA, July 17, 2002, pp. 321-333, Vol. 288, No. 3.	
	65.	SCHNYDER, GUIDO, et al., "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamin	
		B <sub>12</sub> , and Vitamin B <sub>6</sub> on Clinical Outcome After Percutaneous Coronary Intervention," JAMA,	
		August 28, 2002, pp. 973-979, Vol. 288, No. 8.	
	66.	SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent	
		Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156,	
'		Vol. 84.	
	67.	SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in	
		Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102.	
	68.	STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate	
		and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1.	
	69.	STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce	
		Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol.	
		332, No. 5.	
1	70.	STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic	
l U		Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158.	
	71.	STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with	
		Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996,	
V 1		pp. 781-786, Vol. 347.	
	72.	STIPANUK, MARTHA H., "Metabolism of Sulfur-Containing Amino Acids," Ann. Rev. Nutr., 1986,	
		pp. 179-209, Vol. 6.	
	73.	TICE, JEFFREY A., et al., "Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocysteine	$\dagger$
		Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond,"	
		JAMA, August 22/29, 2001, pp. 936-943, Vol. 286.	

		T	
Examiner Signature		Date	
Digitature	<u></u>	Considered	ļ

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SEP 1 1 2003 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary

6 Sheet of 6

Com	plete if Kn wn
Application Numb r	10/635,928
Filing Date	August 6, 2003
First Nam d Inv ntor	Venkataraman
Group Art Unit	
Examiner Name	
Attorney Docket Number	52761/286146

	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS					
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>			
	74.	UELAND, P.M. and REFSUM, H., "Plasma Homocysteine, A Risk Factor For Premature Vascular				
		Disease. Plasma Levels in Healthy Person; During Pathologic Conditions and Drug Therapy,"				
		Nord Med., 1989, pp. 293-308, Vol. 104, No. 11. (Abstract)				
	75.	VALAGUSSA, F., et al., "Dietary Supplementation With N-3 Polyunsaturated Fatty Acids and	1.			
i i		Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial," The Lancet,				
		August 7, 1999, pp. 447-455, Vol. 354.				
	76.	VAN DER KUY, et al., "Hydroxocobalamin, A Nitric Oxide Scavenger, In the Prophylaxis of	1			
		Migraine: An Open, Pilot Study," Cephalalgia Sept. 2002, pp. 513-519, Vol. 22, No. 7,.				
	77.	VERHAAR, MARIANNE C., et al., "Effects of Oral Folic Acid Supplementation on Endothelial				
		Function in Familial Hypercholesterolemia," Circulation, July 27, 1999, pp. 335-338, Vol. 100.				
	78.	VIVANCO, N., et al., "Treatment of Anorexia Nervosa," Rev Med Chil, 1992, pp. 69-75, Vol. 120.				
		(Abstract)				
	79.	WATERS, DAVID D., et al., "Effects of Hormone Replacement Therapy and Antioxidant Vitamin	1			
		Supplements on Coronary Atherosclerosis in Postmenopausal Women," JAMA, November 20,				
		2002, pages 2432-3440, Vol 288, No. 19.				
	80.	YANG, CHUN-YUH, "Calcium and Magnesium in Drinking Water and Risk of Death from				
		Cerebrovascular Disease," Stroke, 1998, pp. 411-414, Vol. 29.	1			

Examiner	Date
Signature	Considered
	Considered

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.